1-7 of 7
Andrew M. Davidoff
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma

Wayne L. Furman, Sara M. Federico, Mary Beth McCarville, Barry L. Shulkin, Andrew M. Davidoff, Matthew J. Krasin, Natasha Sahr, April Sykes, Jianrong Wu, Rachel C. Brennan, Michael William Bishop, Sara Helmig, Elizabeth Stewart, Fariba Navid, Brandon Triplett, Victor M. Santana, Armita Bahrami, Gwendolyn Anthony, Alice L. Yu, Jacquelyn Hank, Stephen D. Gillies, Paul M. Sondel, Wing H. Leung, Alberto S. Pappo
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (21): 6320–6328.
https://doi.org/10.1158/1078-0432.CCR-19-1452
Published: 01 November 2019
View article titled, A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma
Open the PDF for A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma in another window
Includes: Supplementary data
Journal Articles

Phase I Trial, Pharmacokinetics, and Pharmacodynamics of Vandetanib and Dasatinib in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma

Alberto Broniscer, Sharyn D. Baker, Cynthia Wetmore, Atmaram S. Pai Panandiker, Jie Huang, Andrew M. Davidoff, Arzu Onar-Thomas, John C. Panetta, Thomas K. Chin, Thomas E. Merchant, Justin N. Baker, Sue C. Kaste, Amar Gajjar, Clinton F. Stewart
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (11): 3050–3058.
https://doi.org/10.1158/1078-0432.CCR-13-0306
Published: 30 May 2013
View article titled, Phase I Trial, Pharmacokinetics, and Pharmacodynamics of Vandetanib and Dasatinib in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Open the PDF for Phase I Trial, Pharmacokinetics, and Pharmacodynamics of Vandetanib and Dasatinib in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma in another window
Includes: Supplementary data
Journal Articles

Establishment and Characterization of the First Pediatric Adrenocortical Carcinoma Xenograft Model Identifies Topotecan as a Potential Chemotherapeutic Agent

Emilia M. Pinto, Christopher Morton, Carlos Rodriguez-Galindo, Lisa McGregor, Andrew M. Davidoff, Kimberly Mercer, Larisa V. Debelenko, Catherine Billups, Raul C. Ribeiro, Gerard P. Zambetti
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (7): 1740–1747.
https://doi.org/10.1158/1078-0432.CCR-12-3354
Published: 02 April 2013
View article titled, Establishment and Characterization of the First Pediatric Adrenocortical Carcinoma Xenograft Model Identifies Topotecan as a Potential Chemotherapeutic Agent
Open the PDF for Establishment and Characterization of the First Pediatric Adrenocortical Carcinoma Xenograft Model Identifies Topotecan as a Potential Chemotherapeutic Agent in another window
Includes: Supplementary data
Journal Articles

Phase I and Clinical Pharmacology Study of Bevacizumab, Sorafenib, and Low-Dose Cyclophosphamide in Children and Young Adults with Refractory/Recurrent Solid Tumors

Fariba Navid, Sharyn D. Baker, M. Beth McCarville, Clinton F. Stewart, Catherine A. Billups, Jianrong Wu, Andrew M. Davidoff, Sheri L. Spunt, Wayne L. Furman, Lisa M. McGregor, Shuiying Hu, John C. Panetta, David Turner, Demba Fofana, Wilburn E. Reddick, Wing Leung, Victor M. Santana
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (1): 236–246.
https://doi.org/10.1158/1078-0432.CCR-12-1897
Published: 02 January 2013
View article titled, Phase I and Clinical Pharmacology Study of Bevacizumab, Sorafenib, and Low-Dose Cyclophosphamide in Children and Young Adults with Refractory/Recurrent Solid Tumors
Open the PDF for Phase I and Clinical Pharmacology Study of Bevacizumab, Sorafenib, and Low-Dose Cyclophosphamide in Children and Young Adults with Refractory/Recurrent Solid Tumors in another window
Journal Articles

Bevacizumab-Induced Transient Remodeling of the Vasculature in Neuroblastoma Xenografts Results in Improved Delivery and Efficacy of Systemically Administered Chemotherapy

Paxton V. Dickson, John B. Hamner, Thomas L. Sims, Charles H. Fraga, Catherine Y.C. Ng, Surender Rajasekeran, Nikolaus L. Hagedorn, M. Beth McCarville, Clinton F. Stewart, Andrew M. Davidoff
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (13): 3942–3950.
https://doi.org/10.1158/1078-0432.CCR-07-0278
Published: 02 July 2007
View article titled, Bevacizumab-Induced Transient Remodeling of the Vasculature in Neuroblastoma Xenografts Results in Improved Delivery and Efficacy of Systemically Administered Chemotherapy
Open the PDF for Bevacizumab-Induced Transient Remodeling of the Vasculature in Neuroblastoma Xenografts Results in Improved Delivery and Efficacy of Systemically Administered Chemotherapy in another window
Journal Articles

Adeno-Associated Virus Vector-Mediated Systemic Delivery of IFN-β Combined with Low-Dose Cyclophosphamide Affects Tumor Regression in Murine Neuroblastoma Models

Christian J. Streck, Paxton V. Dickson, Catherine Y.C. Ng, Junfang Zhou, John T. Gray, Amit C. Nathwani, Andrew M. Davidoff
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (16): 6020–6029.
https://doi.org/10.1158/1078-0432.CCR-05-0502
Published: 22 August 2005
View article titled, Adeno-Associated Virus Vector-Mediated Systemic Delivery of IFN-β Combined with Low-Dose Cyclophosphamide Affects Tumor Regression in Murine Neuroblastoma Models
Open the PDF for Adeno-Associated Virus Vector-Mediated Systemic Delivery of IFN-β Combined with Low-Dose Cyclophosphamide Affects Tumor Regression in Murine Neuroblastoma Models in another window
Journal Articles

Bone Marrow-derived Cells Contribute to Tumor Neovasculature and, When Modified to Express an Angiogenesis Inhibitor, Can Restrict Tumor Growth in Mice

Andrew M. Davidoff, Catherine Y. C. Ng, Peggy Brown, Margaret A. Leary, William W. Spurbeck, Junfang Zhou, Edwin Horwitz, Elio F. Vanin, Arthur W. Nienhuis
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (9): 2870–2879.
Published: 01 September 2001
View article titled, Bone Marrow-derived Cells Contribute to Tumor Neovasculature and, When Modified to Express an Angiogenesis Inhibitor, Can Restrict Tumor Growth in Mice
Open the PDF for Bone Marrow-derived Cells Contribute to Tumor Neovasculature and, When Modified to Express an Angiogenesis Inhibitor, Can Restrict Tumor Growth in Mice in another window